Zhejiang Hisoar Pharmaceutical Hits Day Low of CNY 7.22 Amid Price Pressure

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.93% and reaching an intraday low of CNY 7.22. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 1.26% during the same period. Over the past week, Zhejiang Hisoar has seen a significant decrease of 16.99%, while its performance over the last month shows a gain of 7.32%. However, the company's longer-term outlook appears mixed, with a year-to-date increase of 17.47% and a one-year performance of 60.04%, both outperforming the China Shanghai Composite. Despite these gains, the company faces challenges, including a low Return on Capital Employed (ROCE) of 2.16%, indicating limited profitability relative to its capital. Additionally, the company has reported a decline in net sales and operating profit over the past five years, raising concerns about its long-term growth prospects. With a market capitalization of CNY 11,906 million, Zhejiang Hisoar remains a significant player in the pharmaceuticals and biotechnology sector, though its recent performance highlights the volatility and risks associated with its stock.